December 8, 2024Open Access

Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease

MDMatthew S. DavidsHarvard University CRChristine E. RyanDana-Farber Cancer Institute BLBenjamin L. LampsonBroad Institute

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

AVO was highly active and well tolerated in patients with previously untreated high-risk CLL, supporting its use as a new standard-of-care treatment option.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Davids et al. (Sun,) studied this question.

synapsesocial.com/papers/69df6e4258b92af24d7a18da https://doi.org/https://doi.org/10.1200/jco-24-02503

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL2018 · 1,708 citations
2Tumour lysis syndrome: new therapeutic strategies and classification2004 · 1,064 citations
3Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group2012 · 433 citations
4Ibrutinib for Chronic Lymphocytic Leukemia with <i>TP53</i> Alterations2020 · 115 citations
5Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia2015 · 219 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo